Article Listing - Good news for Britain’s RA patients as NICE backs NHS use of MabThera and Humira, as well as Enbrel, Remicade, Orencia and RoActemra in some circumstances

SOMBRE FUTURE FOR GENERALIST DRUG-MAKERS IN FRANCE?

9 March 1992

In contrast to specialist drug firms such as Innothera, which successfully exploit a niche in the drug market, generalist pharmaceutical...

ROCHE CENTER ESTABLISHED IN USA

9 March 1992

A new study center for nervous system injuries at Washington University in St Louis, Missouri, is being set up to...

TURNOVER UP 39% AT LUNDBECK UK

9 March 1992

In the UK, pharmaceutical concern Lundbeck says it is set for a healthy future following its latest annual results. For...

ROCHE TO PROMOTE GENENTECH'S DNase

9 March 1992

Swiss major Hoffmann-La Roche and Californian biotechnology concern Genentech last week announced four different international R&D agreements using their combined...

WARNING LETTER TO MILES ON NIMOTOP

9 March 1992

Promotion of the neurone-specific calcium channel blocker Nimotop (nimodipine) in the USA by Miles Laboratories for the unapproved indication of...

ORPHAN DRUG BILL FACES VETO

9 March 1992

Sponsors of legislation now in the Senate which would reduce the market monopoly enjoyed by orphan drug makers fear that...

MEDEVA'S NEW CORACTEN FORM

9 March 1992

Medeva plc and its subsidiary Evans Medical have launched in the UK a new product in the Coracten (nifedipine) range....

HUMAN CARCINOMA ANTIGEN

9 March 1992

Massachusetts-based company Epigen Inc has signed an agreement with investigators at the University of Oslo, Norway, to characterize the HC...

US APPROVAL FOR CARDENE SR

9 March 1992

Syntex Corp has received approval from the US Food and Drug Administration to market its Cardene SR, a slow-release formulation...

BIOCHEM PHARMA'S JOHN GILLARD

9 March 1992

John Gillard has been appointed as director of therapeutic research at BioChem Pharma Inc of Canada. 1614869 COST CONTAINMENT MEASURES...

Showing 94751-94760 of 95353 articles